The ibogaine juvenile plasticity finding will generate at least 3 NIH R01 grant awards (not merely applications) specifically targeting critical period plasticity mechanisms within 18 months of May 2026.

A recent discovery that ibogaine (a psychedelic) can reopen brain plasticity windows in adults is so important that the NIH (US medical research agency) will likely fund at least three R01 grants (major research awards) specifically to study how this works. This is aggressive because NIH typically funds only 1 in 5 grant proposals, and the finding needs time to get recognized and peer-reviewed. Within 18 months of May 2026 (by late 2027) is the deadline.

Critical period reopening in adult cortex via a single compound is a genuinely field-reorganizing result if replicated. However, the prediction as originally stated conflates grant cycles initiated with grants funded: R01 cycles run 6-9 months from application to award, and study sections must first recognize the finding as fundable. Three funded R01s within 18 months is aggressive given NIH funding rates (~20%) and the replication uncertainty inherent in a novel finding. Revising to 'awards' rather than 'cycles targeting' makes this falsifiable. Confidence reduced accordingly.